SCHEDULE: Squadron Master Fund Reports 9.99% Stake in Pasithea Therapeutics

Squadron Master Fund LP and related entities disclose a 9.99% beneficial ownership stake in Pasithea Therapeutics Corp. common stock.

Summary

• Squadron Master Fund LP, Squadron Capital Management LLC, Matthew Sesterhenn, and William Blank collectively reported beneficial ownership of 2,329,749 shares of Pasithea Therapeutics Corp. Common Stock.
• This ownership represents approximately 9.99% of the issuer's outstanding Common Stock.
• The reported stake comprises 2,100,000 shares of Common Stock and 229,749 shares issuable upon the exercise of warrants.
• The reporting persons explicitly disclaim beneficial ownership over the securities, stating the filing should not be construed as an admission of beneficial ownership.
• The securities were acquired and are held in the ordinary course of business, without the purpose or effect of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral disclosure, providing transparency on a significant passive ownership stake without indicating any strategic shifts or performance implications for Pasithea Therapeutics Corp.

Positives

• Increased transparency regarding a significant institutional ownership stake in Pasithea Therapeutics Corp.
• The explicit statement that the securities were acquired and are held in the ordinary course of business, not for changing or influencing control, indicates a passive investment approach.

Negatives

• No explicit negatives are presented in this factual ownership disclosure.

Risks

• The reporting persons, Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, expressly disclaim beneficial ownership over the reported securities, which is a legal nuance regarding their ultimate control or influence.

Future Outlook

The filing does not contain any forward-looking statements or guidance from the issuer or the reporting persons beyond the passive nature of the investment.

Management Comments

• The securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for passive investors holding more than 5% of a company's stock. This filing indicates a significant, but non-activist, stake in Pasithea Therapeutics Corp., which is a common occurrence for investment funds and provides market transparency regarding ownership structure.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant institutional holder's stake in the company.
• Management: Awareness of a large passive investor, but no immediate pressure for strategic or operational changes given the nature of a Schedule 13G filing.

Next Steps

• No specific future actions, events, or milestones are mentioned by the reporting persons or the issuer in this filing.

Key Dates

Recommendation

The Schedule 13G filing merely discloses a significant passive ownership stake by Squadron Master Fund LP and related entities in Pasithea Therapeutics Corp. It does not contain new financial performance data, strategic updates, or activist intentions that would warrant a change in investment recommendation. The investment is stated to be in the ordinary course of business, suggesting no immediate catalyst for significant price movement based solely on this filing. Therefore, a 'hold' recommendation is appropriate as investors should continue to evaluate the company based on its operational performance and broader market conditions.

Keywords

Pasithea Therapeutics, Squadron Master Fund, Squadron Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, Investment Adviser, Passive Investment